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Radiofrequency ablation (RFA) is a treatment option in the management of unresectable or recurrent
hepatocellular carcinoma (HCC). It can be performed either through laparotomy or in a minimally inva-
sive manner by percutaneous, laparoscopic or thoracoscopic routes. Percutaneous RFA is associated with
reduced surgical trauma and thus can be performed in patients with significant comorbidities. The pro-
cedure can be repeated after short intervals for sequential ablation of multiple liver lesions. However, the
associated risks should not be underestimated. This is the first report of a rare complication of duodeno-
pleural fistula after percutaneous RFA of a recurrent subcapsular HCC. The risk of bowel perforation
during the ablation of subcapsular HCC requires special attention, since only the position of the tip of
the electrode, but not the zone of ablation, can be assessed accurately by imaging during the procedure.
Our case demonstrated that there was leakage of bowel content from the duodenal injury site into the
pleural cavity through the RFA track. Subsequent uncontrolled infection resulted in empyema thoracis
and led to the death of the patient. [Asian J Surg 2007;30(4):278–82]
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Introduction
Radiofrequency ablation (RFA) for the treatment of liver
tumours is currently widely practiced around the world.
It has the advantage of localized tumour ablation and
preservation of maximal normal liver parenchyma.1 Most
studies focus on its efficacy in tumour ablation. The
reported complete ablation rate of RFA for hepatocellular
carcinoma (HCC) approaches 100% in some studies.2,3
The local recurrence rate is low and ranges from 3.6% to
15%.3–7 It is generally performed for unresectable primary
or metastatic liver tumours. The reported 3-year and 
5-year survival rates of RFA for HCC were 33–45%6,8 and
33%,4 respectively. However, a recent prospective study by
Raut et al reported a significant improvement in 5-year
survival of 55.4% in patients with RFA of unresectable
HCC confined to the liver.5 The improvement in outcome
of HCC patients treated with RFA was partly attributed
to the advance in instrumentation. In the in vivo animal
study by Lee et al, bipolar RFA produced a larger coagula-
tion volume than the monopolar mode and was not asso-
ciated with significant complications.9 The role of RFA in
the treatment of liver tumours is expanding, and it may
be a potentially curative treatment for HCC.
RFA can be performed in a minimally invasive manner
via the percutaneous route under imaging guidance, or
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using a laparoscopic or thoracoscopic approach in suit-
able situations. Nonetheless, there is a lack of guidelines
for selection of patients for treatment by minimally inva-
sive routes for RFA. Even when performed using a mini-
mally invasive route, a wide spectrum of complications
has been reported since its clinical application. The
reported overall mortality rate was 0.5% and morbidity
rate was 8.9% from a review of the literature.10 Major com-
plications reported in this review included abdominal
bleeding, intra-abdominal sepsis, bile duct injury, liver
failure, cardiopulmonary complications, skin burn at
ground pad site, visceral damage and renal failure. We
report a patient who suffered a rare complication of duo-
denopleural fistula after RFA of a liver tumour via the
percutaneous route. To our knowledge, this is the first
case report describing this rare complication after RFA.
Case report
The patient was a 64-year-old chronic hepatitis B carrier. She
was diagnosed to have HCC with a serum α-fetoprotein
(AFP) concentration of 14 ng/mL. There was a 6-cm soli-
tary tumour over the right lobe of the liver on the com-
puted tomography (CT) scan. The tumour was considered
unresectable due to poor liver function (serum bilirubin,
30 µmol/L; serum albumin, 22 g/L; platelets, 61 × 109/L;
prothrombin time, 24.2 seconds; indocyanine green reten-
tion rate, 32.9% at 15 minutes). She was initially managed
by transarterial chemoembolization (TACE). However,
the tumour failed to respond to TACE and serum AFP
concentration increased to 218 ng/mL. In the absence of
extrahepatic disease, the patient underwent laparotomy,
cholecystectomy and RFA of the lesion. The tumour was
ablated by clustered internally cooled tip electrodes for 
a total duration of 288 minutes. Immediately before the
procedure, a core biopsy of the liver tumour was taken
and the diagnosis of HCC was confirmed histologically.
Recovery after this RFA was uneventful. The tumour was
completely ablated as evidenced by a CT scan and reduction
in serum AFP to 10 ng/mL.
The patient was disease-free for the subsequent 
20 months. Afterwards, she developed intrahepatic recur-
rence and received multiple sessions of percutaneous 
CT-guided RFA as the tumour was not well shown on
ultrasound. The last session of CT-guided RFA was per-
formed on a 2-cm liver tumour in segment VI (Figure 1).
The tumour was punctured by two single internally
cooled tip electrodes with a 3-cm tip exposure using the
cool-tip® RF system (Radionics, Burlington, MA, USA).
The lesion was ablated twice and the total duration of
ablation was 21 minutes. She was asymptomatic after the
procedure and was discharged on the third day with an
antibiotic (oral Augmentin®) and an H2 antagonist. The
patient was well and asymptomatic during outpatient 
follow-up on day 20. However, she developed sudden
onset of shortness of breath on day 25. She was in a semi-
conscious state on arrival at the hospital, with imminent
respiratory arrest. There were decreased breath sounds
over the right lung on chest auscultation. Endotracheal
intubation and mechanical ventilation were required for
respiratory support. Chest X-ray showed gross right pleural
effusion (Figure 2). A contrast CT scan of the thorax and
abdomen revealed empyema thoracis (Figure 3). The pleu-
ral fluid cultures showed a mixed growth of Streptococcus,
Klebsiella and Candida. A subsequent non-ionic contrast
study demonstrated leakage of contrast medium from the
first part of the duodenum to the right pleural cavity, indi-
cating the presence of a duodenopleural fistula (Figure 4).
Despite maximal support and broad spectrum antibiotics,
the septic condition was not controlled. The patient devel-
oped multiorgan failure and died 4 days after admission.
Discussion
HCC is usually associated with liver cirrhosis in patients
with chronic viral hepatitis status, rendering resection not
Figure 1. Computed tomography-guided percutaneous radio-
frequency ablation of recurrent hepatocellular carcinoma (white
arrow). Black arrow indicates the close proximity of the duodenum
to the live tumour.
possible in many cases even for small HCC. Advancement
in local ablation therapies has led to a major breakthrough
in the management of unresectable HCC. RFA can be safely
performed in patients with unresectable HCC due to poor
liver reserve, multifocal disease and close proximity of the
tumour to major vessels. Poor liver reserve is reflected by
high bilirubin concentration, low albumin level and pro-
longed clotting time, as well as high indocyanine green
retention rate. Functional liver parenchyma can be pre-
served after RFA and the risk of liver failure is minimized.
Furthermore, RFA by the percutaneous route allows
patients with concomitant comorbidities who are not fit
for major surgery under general anaesthesia to undergo
this potentially curative treatment under local anaesthesia.
This minimally invasive approach allows fast recovery of
patients and shortens hospital stay. Although there is
concern about incomplete ablation in respect of the mul-
tiplicity and large size of liver tumours, it can be overcome
by repeating the procedure on a weekly or biweekly basis.
Nevertheless, potential risks associated with RFA treat-
ment should not be underestimated.
An exhaustive review of the reported complications by
Mulier et al concluded that the morbidity and mortality
of RFA are often underestimated because minor and
delayed complications are ignored.10 From their review of
82 independent reports, there were 3,670 patients treated
with percutaneous, laparoscopic or open RFA. The over-
all mortality rate was 0.5% and morbidity rate was 8.9%,
which were higher than previously assumed. Abdominal
bleeding, abdominal infection, biliary tract damage, liver
failure and pulmonary complications were commonly
reported after RFA of HCC. Adequate knowledge of the
potential risk of application of RFA via different routes is
essential for avoidance of these preventable complications.10
A prospective study of 582 malignant liver tumours, by
either open or percutaneous routes, in 312 patients sug-
gested a higher risk of liver abscess in patients with a bil-
ioenteric anastomosis and a higher frequency of portal
vein thrombosis after open RFA with the Pringle manoeu-
vre in patients with cirrhotic livers.11 In another prospective
study by Curley et al on the early and late complications
after RFA of 1,225 malignant liver tumours in 608 patients,
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Figure 2. Chest X-ray shows right pleural effusion.
Figure 3. Computed tomography shows massive right pleural
effusion and small left pleural effusion.
Figure 4. Oral contrast study demonstrates a fistula between the
duodenum and the right pleural cavity (arrow).
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the open approach and liver cirrhosis were associated
with a significantly higher rate of early complications that
occurred within 30 days of treatment.3 There was no sig-
nificant prognostic factor predictive of late complica-
tions. Poon et al studied 100 patients with malignant liver
tumours managed by percutaneous, open or laparoscopic
RFA.2 In an attempt to evaluate the effect of operator expe-
rience on RFA outcome, a comparison of the first 50 and the
second 50 patients was done. An elevated serum bilirubin
level (> 20 µmol/L) and treatment group were independent
factors associated with RFA-related complications.
Although a variety of complications were mentioned
in previous reviews, enteropleural fistula following RFA
has not been reported in the literature so far. In our case,
the possible mechanisms of bowel injury could be caused
by (1) direct perforation of the bowel by sharp electrodes
which penetrated through the liver capsule during the
procedure, and (2) thermal damage by heat generated and
conducted to the duodenum adjacent to the subcapsular
liver tumour, resulting in delayed perforation of the 
duodenal wall. This could have been enhanced by adhe-
sions between the liver and the duodenum following pre-
vious laparotomy. Leakage of duodenal content tracking
into the pleural cavity probably through the puncture site
of the diaphragm where the electrode went into the liver
and the subsequent infection resulted in empyema tho-
racis. There have been reports of damage of adjacent
organs like the gallbladder, stomach, colon, kidney, heart
and lung by RFA.10 In addition, the liver parenchyma, bile
ducts and intrahepatic vessels are all susceptible to injury
by RFA as well.12
Mulier et al suggested no difference in complication
rate with respect to different approaches by percutaneous,
laparoscopic and simple open routes.10 However, as
shown in our case, percutaneous RFA of the liver tumour
is not a good choice in certain specific clinical situations.
The close proximity of the bowel to the targeted lesion at
a subcapsular location is not favourable for percutaneous
RFA. Despite advances in imaging techniques, only the
position of the tip of the electrode can be assessed accu-
rately, while the depth of ablation beyond the tip of the
electrode cannot, which may result in thermal burn of the
adjacent structures.13 Inadvertent bowel perforation is
potentially lethal as spillage of bowel contents may lead
to peritonitis or empyema thoracis, as in our patient.
Some interventional radiologists employ infusion of dex-
trose solution into the peritoneal cavity to move away
adjacent viscera and reduce the risk of bowel perforation
during percutaneous RFA of a liver tumour close to viscera.
However, that may not have been useful in our case because
of the presence of adhesions following previous laparo-
tomy. In such a scenario, we advocate an open approach
to mobilize the liver and shield these organs away from
the ablation field. In addition, cholecystectomy is some-
times mandatory before ablation of subcapsular tumours
located at segment IV or V.
In summary, RFA, considered a minimally invasive treat-
ment of liver lesions, could be associated with potential
lethal complications. A better understanding and careful
assessment of the tumour and the approach of the proce-
dure are of paramount importance in preventing patient
morbidity and death. Despite a minimally invasive tech-
nique by the percutaneous approach, enteropleural fistula
may occur if the bowel is in close proximity to the target
lesion. It may result in empyema thoracis which is a poten-
tially fatal complication. Thus, extra caution should be
taken to avoid adjacent bowel injury during RFA.
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